| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Research Communications |
* Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, 33006 Oviedo, Spain; and
Hospital de Jove, 33212 Gijón, Spain
1Correspondence: Departamento de Bioquímica y Biología Molecular. Facultad de Medicina. Universidad de Oviedo, 33006 Oviedo. Spain. E-mail: SRG{at}sauron.quimica.uniovi.es
The present study shows that melatonin prevents, within the first cell cycle, the estradiol-induced growth of synchronized MCF7 breast cancer cells. By using nuclear extracts of these cells, we first examined the binding of estradiol–estrogen receptor complexes to estrogen-responsive elements and found that the addition of estradiol to whole cells activates the binding of the estrogen receptor to DNA whereas melatonin blocks this interaction. By contrast, melatonin neither affects the binding of estradiol to its receptor nor the receptor nuclear localization. Moreover, we also show that addition of estradiol to nuclear extracts stimulates the binding of estrogen receptor to DNA, but this activation is also prevented by melatonin. The inhibitory effect caused by melatonin is saturable at nanomolar concentrations and does not appear to be mediated by RZR nuclear receptors. The effect is also specific, since indol derivatives do not cause significant inhibition. Furthermore, we provide evidence that melatonin does not interact with the estrogen receptor in the absence of estradiol. Together, these results demonstrate that melatonin interferes with the activation of estrogen receptor by estradiol. The effect of melatonin suggests the presence of a receptor that, upon melatonin addition, destabilizes the binding of the estradiol–estrogen receptor complex to the estrogen responsive element.—Rato, A. G., Pedrero, J. G., Martínez, M. A., del Rio, B., Lazo, P. S., Ramos, S. Melatonin blocks the activation of estrogen receptor for DNA binding.
Key Words: antiestrogen • breast cancer • estradiol • MCF7 cells
This article has been cited by other articles:
|
|
 |
|
  E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Srinivasan, D W. Spence, S. R. Pandi-Perumal, I. Trakht, and D. P. Cardinali Therapeutic Actions of Melatonin in Cancer: Possible Mechanisms Integr Cancer Ther, September 1, 2008; 7(3): 189 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Presman, E. Hoijman, N. R. Ceballos, M. D. Galigniana, and A. Pecci Melatonin Inhibits Glucocorticoid Receptor Nuclear Translocation in Mouse Thymocytes Endocrinology, November 1, 2006; 147(11): 5452 - 5459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. del Rio, J. M. G. Pedrero, C. Martinez-Campa, P. Zuazua, P. S. Lazo, and S. Ramos Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor {alpha} via Calmodulin J. Biol. Chem., September 10, 2004; 279(37): 38294 - 38302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Izzo, M. d'Istria, I. Serino, and S. Minucci Inhibition of the increased 17{beta}-estradiol-induced mast cell number by melatonin in the testis of the frog Rana esculenta, in vivo and in vitro J. Exp. Biol., February 1, 2004; 207(3): 437 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Garcia Pedrero, P. Zuazua, C. Martinez-Campa, P. S. Lazo, and S. Ramos The Naturally Occurring Variant of Estrogen Receptor (ER) ER{Delta}E7 Suppresses Estrogen-Dependent Transcriptional Activation by Both Wild-Type ER{alpha} and ER{beta} Endocrinology, July 1, 2003; 144(7): 2967 - 2976. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
